Page last updated: 2024-11-05

chrysene

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Chrysene is a polycyclic aromatic hydrocarbon (PAH) with the molecular formula C18H12. It is a colorless, crystalline solid that is found in coal tar, petroleum, and tobacco smoke. Chrysene is a known carcinogen and has been linked to an increased risk of lung cancer. It is also a potent mutagen, meaning that it can cause mutations in DNA. Chrysene is studied because it is a common environmental contaminant and is a potential health hazard. It is also a model compound for studying the properties of PAHs. Chrysene can be synthesized by a variety of methods, including the pyrolysis of coal and the condensation of aromatic compounds. It is also produced as a byproduct of various industrial processes, such as the combustion of fossil fuels. Chrysene is a relatively stable compound and can persist in the environment for long periods of time. It is also poorly soluble in water, which makes it difficult to remove from the environment.'

chrysene: structure in Merck Index, 9th ed, #2252 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

chrysene : An ortho-fused polycyclic arene found commonly in the coal tar. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID9171
CHEMBL ID85685
CHEBI ID51687
MeSH IDM0098157

Synonyms (63)

Synonym
BIDD:ER0418
CHEMBL85685 ,
nsc6175
218-01-9
benzo[a]phenanthrene
nsc-6175
benz[a]phenanthrene
wln: l e6 b666j
chrysene
1,2-benzphenanthrene
1,2-benzophenanthrene
1,5,6-dibenzonaphthalene
1,2,5,6-dibenzonaphthalene
ai3-00867
nsc 6175
benz(a)phenanthrene
einecs 205-923-4
benzo(a)phenanthrene
rcra waste no. u050
ccris 161
rcra waste number u050
coal tar pitch volatiles: chrysene
hsdb 2810
chrysene, 95%
NCGC00163986-01
chrysen
CHEBI:51687 ,
bdbm50128870
65777-08-4
084hcm49pt ,
unii-084hcm49pt
NCGC00260097-01
tox21_202548
cas-218-01-9
dtxcid702432
dtxsid0022432 ,
A815674
FT-0623810
FT-0633792
AKOS015904682
chrysene [hsdb]
(4)phenacene
chrysene [iarc]
chrysene [mi]
W-201895
chrysene, certified reference material, tracecert(r)
chrysene, bcr(r) certified reference material
mfcd00003698
chrysene, 98%
chrysene, analytical standard
chrysene 100 microg/ml in acetonitrile
chrysene 10 microg/ml in acetonitrile
chrysene 10 microg/ml in cyclohexane
Q415465
benzo[a]phenanthrene (purified by sublimation)
chrysenensc 6175
AS-39344
AMY18784
CS-0079473
HY-121107
SY048799
benzo (a) phenanthrene
chrysene (iarc)

Research Excerpts

Toxicity

This study aims to investigate potential toxic effects of chrysene on mature scallop Chlamys farreri during the reproduction period. Based on the prevalence of signs of blue sac disease (BSD), as expressed by median effective concentrations (EC50s), benz[a]anthracene (B[a].A) was more toxic than ch Chrysene.

ExcerptReferenceRelevance
" The polycyclic aromatic hydrocarbons (PAHs) were not highly toxic to either bacterial strain; the toxicity of their degradation products depended on the method of chemical processing."( Microbiological evaluation of toxicity of three polycyclic aromatic hydrocarbons and their decomposition products formed by advanced oxidation processes.
Jamroz, T; Ledakowicz, S; Miller, JS; Sencio, B, 2003
)
0.32
"This study evaluates the toxic effects of chrysene (a component from cigarette smoke) on Müller cells (MIO-M1) in vitro and investigates whether the inhibitor lipoic acid can reverse the chrysene-induced toxic effects."( Protective effects of lipoic acid on chrysene-induced toxicity on Müller cells in vitro.
Gupta, N; Kenney, MC; Kuppermann, BD; Limb, GA; Luczy-Bachman, G; Mansoor, S, 2013
)
0.93
" Based on the prevalence of signs of blue sac disease (BSD), as expressed by median effective concentrations (EC50s), benz[a]anthracene (B[a]A) was more toxic than chrysene."( Quantitative structure-activity relationships for chronic toxicity of alkyl-chrysenes and alkyl-benz[a]anthracenes to Japanese medaka embryos (Oryzias latipes).
Brown, RS; Hodson, PV; Jørgensen, KB; Lin, H; Morandi, GD; Rantanen, T; Snieckus, V, 2015
)
0.84
"This study aims to investigate potential toxic effects of chrysene (CHR) on mature scallop Chlamys farreri during the reproduction period, using indicators of antioxidant defences and oxidative stress."( Toxic effects upon exposure to polycyclic aromatic hydrocarbon (chrysene) in scallop Chlamys farreri during the reproduction period.
Jin, Q; Pan, L; Xiu, M, 2016
)
0.92

Pharmacokinetics

ExcerptReferenceRelevance
" To understand the implications of dose and species differences, a physiologically based pharmacokinetic model (PBPK) for DBC and major metabolites was developed in mice and humans."( Translating dosimetry of Dibenzo[def,p]chrysene (DBC) and metabolites across dose and species using physiologically based pharmacokinetic (PBPK) modeling.
Corley, RA; Crowell, SR; Madeen, EP; Ognibene, TJ; Pande, P; Smith, JN; Turteltaub, KW; Williams, DE, 2022
)
0.99

Bioavailability

ExcerptReferenceRelevance
"Accurate estimates for the oral bioavailability of hydrophobic contaminants bound to solid matrices are challenging to obtain because of sorption to organic matter."( Mobilization of chrysene from soil in a model digestive system.
Gobas, FA; Minhas, JK; Moore, MM; Pinto, LJ; Vasiluk, L, 2006
)
0.68
" It is hypothesized that the lack of PAH bioavailability hampered their further biodegradation in the unspiked soil."( Microbial populations related to PAH biodegradation in an aged biostimulated creosote-contaminated soil.
Jiménez, N; Lladó, S; Solanas, AM; Viñas, M, 2009
)
0.35
" This study supports the use of bile fluorescence in Nile tilapia by fixed wavelength fluorescence and synchronous fluorescence spectrometry with non-normalized data as a simple method for screening bioavailability of these PAHs."( Assessment of bile fluorescence patterns in a tropical fish, Nile tilapia (Oreochromis niloticus) exposed to naphthalene, phenanthrene, pyrene and chrysene using fixed wavelength fluorescence and synchronous fluorescence spectrometry.
Hemachandra, CK; Pathiratne, A; Pathiratne, KA, 2010
)
0.56
" Due to their general high abundance in lignites and the toxicity observed for the lignite extract, the mechanism-specific toxicity and bioavailability of these compounds were investigated in the present study using the approach of effect-directed analysis."( Mutagenicity, dioxin-like activity and bioaccumulation of alkylated picene and chrysene derivatives in a German lignite.
Achten, C; Christ, A; Hollert, H; Meyer, W; Püttmann, W; Redelstein, R; Seiler, TB, 2014
)
0.63

Dosage Studied

ExcerptRelevanceReference
" Besides, dependence of theophylline elimination rate constant on the time of chrysene dosing was also shown."( The effect of chrysene and some polycyclic aromatic hydrocarbons on the elimination of theophylline in rats.
Brandys, J; Piekoszewski, W, 1985
)
0.86
" The study develops conceptual dose-response functions for the different vehicle configurations."( Monitoring the inflammatory potential of exhaust particles from passenger cars in mice.
Cheung, K; Ntziachristos, L; Samaras, Z; Sioutas, C; Stoeger, T; Tzamkiozis, T, 2010
)
0.36
" The present study compares thin-film and solvent-delivery dosing techniques as well as single versus multiple chemical dosing for measuring biotransformation rates of selected polycyclic aromatic hydrocarbons in rainbow trout (Oncorhynchus mykiss) liver S9."( In vitro biotransformation rates in fish liver S9: effect of dosing techniques.
Delafoulhouze, M; Gobas, FA; Kennedy, CJ; Lee, DH; Lee, YS; Moore, MM; Otton, SV, 2014
)
0.4
" Depletion rate constants measured using thin-film sorbent dosing experiments were not statistically different from the maximum depletion rate constants derived using a series of solvent delivery-based depletion experiments for 3 of the 4 test chemicals."( Concentration dependence of biotransformation in fish liver S9: Optimizing substrate concentrations to estimate hepatic clearance for bioaccumulation assessment.
Allard, GN; Campbell, DA; Gobas, FA; Lo, JC; Otton, SV, 2015
)
0.42
" PBPK model simulations were evaluated against mice dosed with 15 mg/kg DBC by oral gavage and human volunteers orally microdosed with 29 ng of DBC."( Translating dosimetry of Dibenzo[def,p]chrysene (DBC) and metabolites across dose and species using physiologically based pharmacokinetic (PBPK) modeling.
Corley, RA; Crowell, SR; Madeen, EP; Ognibene, TJ; Pande, P; Smith, JN; Turteltaub, KW; Williams, DE, 2022
)
0.99
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
plant metaboliteAny eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
ortho-fused polycyclic arene
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (18)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
LuciferasePhotinus pyralis (common eastern firefly)Potency1.28870.007215.758889.3584AID1224835
pregnane X receptorRattus norvegicus (Norway rat)Potency1.99530.025127.9203501.1870AID651751
RAR-related orphan receptor gammaMus musculus (house mouse)Potency2.50030.006038.004119,952.5996AID1159521; AID1159523
AR proteinHomo sapiens (human)Potency5.56060.000221.22318,912.5098AID1259381
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency27.86890.001022.650876.6163AID1224839
progesterone receptorHomo sapiens (human)Potency7.33110.000417.946075.1148AID1346784; AID1346795
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency5.72530.003041.611522,387.1992AID1159552; AID1159553; AID1159555
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency2.49740.001530.607315,848.9004AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403
pregnane X nuclear receptorHomo sapiens (human)Potency70.79460.005428.02631,258.9301AID720659
estrogen nuclear receptor alphaHomo sapiens (human)Potency21.02020.000229.305416,493.5996AID743075; AID743079
aryl hydrocarbon receptorHomo sapiens (human)Potency6.38190.000723.06741,258.9301AID651777; AID743085; AID743122
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency3.50850.001723.839378.1014AID743083
Histone H2A.xCricetulus griseus (Chinese hamster)Potency57.82600.039147.5451146.8240AID1224845
histone deacetylase 9 isoform 3Homo sapiens (human)Potency6.80460.037617.082361.1927AID1259364; AID1259388
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency14.79550.000627.21521,122.0200AID651741; AID720636; AID743202; AID743219
ATPase family AAA domain-containing protein 5Homo sapiens (human)Potency0.88130.011917.942071.5630AID651632; AID720516
Ataxin-2Homo sapiens (human)Potency0.88130.011912.222168.7989AID651632
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Hypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)Ki8.98000.60005.54678.9800AID93178
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (42)

Processvia Protein(s)Taxonomy
T cell mediated cytotoxicityHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
response to amphetamineHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
purine nucleotide biosynthetic processHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
purine ribonucleoside salvageHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
guanine salvageHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
grooming behaviorHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
locomotory behaviorHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
striatum developmentHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
cerebral cortex neuron differentiationHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
central nervous system neuron developmentHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
GMP salvageHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
IMP salvageHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
dopamine metabolic processHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
hypoxanthine salvageHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
AMP salvageHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
positive regulation of dopamine metabolic processHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
GMP catabolic processHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
IMP metabolic processHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
adenine metabolic processHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
hypoxanthine metabolic processHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
lymphocyte proliferationHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
dendrite morphogenesisHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
protein homotetramerizationHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
dopaminergic neuron differentiationHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
cell population proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of B cell proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
nuclear DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
signal transduction in response to DNA damageATPase family AAA domain-containing protein 5Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
isotype switchingATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of isotype switching to IgG isotypesATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloadingATPase family AAA domain-containing protein 5Homo sapiens (human)
regulation of mitotic cell cycle phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of cell cycle G2/M phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of receptor internalizationAtaxin-2Homo sapiens (human)
regulation of translationAtaxin-2Homo sapiens (human)
RNA metabolic processAtaxin-2Homo sapiens (human)
P-body assemblyAtaxin-2Homo sapiens (human)
stress granule assemblyAtaxin-2Homo sapiens (human)
RNA transportAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (13)

Processvia Protein(s)Taxonomy
nucleotide bindingHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
magnesium ion bindingHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
hypoxanthine phosphoribosyltransferase activityHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
protein bindingHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
identical protein bindingHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
guanine phosphoribosyltransferase activityHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
protein bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP hydrolysis activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloader activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
RNA bindingAtaxin-2Homo sapiens (human)
epidermal growth factor receptor bindingAtaxin-2Homo sapiens (human)
protein bindingAtaxin-2Homo sapiens (human)
mRNA bindingAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (11)

Processvia Protein(s)Taxonomy
cytoplasmHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
cytosolHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
extracellular exosomeHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
cytosolHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
Elg1 RFC-like complexATPase family AAA domain-containing protein 5Homo sapiens (human)
nucleusATPase family AAA domain-containing protein 5Homo sapiens (human)
cytoplasmAtaxin-2Homo sapiens (human)
Golgi apparatusAtaxin-2Homo sapiens (human)
trans-Golgi networkAtaxin-2Homo sapiens (human)
cytosolAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
membraneAtaxin-2Homo sapiens (human)
perinuclear region of cytoplasmAtaxin-2Homo sapiens (human)
ribonucleoprotein complexAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID160321Competition for [3H]benzo[a]pyrene-binding site of polycyclic aromatic hydrocarbon binding protein (PBP) from mouse liver1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Voronoi binding site model of a polycyclic aromatic hydrocarbon binding protein.
AID603957Octanol-water partition coefficient, log P of the compound2008European journal of medicinal chemistry, Apr, Volume: 43, Issue:4
QSPR modeling of octanol/water partition coefficient for vitamins by optimal descriptors calculated with SMILES.
AID93178Kinetic inhibition constant of compound with Trypanosoma cruzi Hypoxanthine Phosphoribosyltransferase (HPRT)2003Journal of medicinal chemistry, Jun-05, Volume: 46, Issue:12
Analysis of 6-(2,2-Dichloroacetamido)chrysene interaction with the hypoxanthine phosphoribosyltransferase from Trypanosoma cruzi.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (210)

TimeframeStudies, This Drug (%)All Drugs %
pre-199032 (15.24)18.7374
1990's25 (11.90)18.2507
2000's52 (24.76)29.6817
2010's79 (37.62)24.3611
2020's22 (10.48)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 49.55

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index49.55 (24.57)
Research Supply Index5.38 (2.92)
Research Growth Index4.79 (4.65)
Search Engine Demand Index78.57 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (49.55)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews4 (1.84%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other213 (98.16%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]